Record Nr. UNINA9910300085703321 Titolo Rare Lymphomas / / edited by Martin Dreyling, Michael E. Williams Berlin, Heidelberg:,: Springer Berlin Heidelberg:,: Imprint: Springer, Pubbl/distr/stampa 2014 **ISBN** 3-642-39590-2 Edizione [1st ed. 2014.] 1 online resource (365 p.) Descrizione fisica Hematologic Malignancies, , 2197-9766 Collana Disciplina 616 616.99/446 616.9944 Soggetti Hematology Oncology Oncology Lingua di pubblicazione Inglese **Formato** Materiale a stampa Livello bibliografico Monografia Note generali Description based upon print version of record. Nota di bibliografia Includes bibliographical references at the end of each chapters. Nota di contenuto I General: Pathology -- Cytogenetics -- Molecular Genetics -- Signal Pathways -- II Disease-specific: T-NHL: Acute T-cell leukemia --Anaplastic lymphoma -- Nasal/NK-cell lymphoma -- Cutaneous T-cell lymphoma -- B-NHL: Adult Burkitt -- Primary Mediastinal Lymphoma -- CNS Lymphoma -- HIV-Associated lymphoma -- Marginal Zone Lymphoma -- MALT -- MCL -- Waldenstroem -- PLL -- Llymphocyte Predominant Hodgkin -- Cutaneous B-cell lymphoma. The past decade has witnessed tremendous progress in the diagnostic Sommario/riassunto and therapeutic approaches to malignant lymphoma as well as in understanding of the underlying molecular pathogenesis. Optimal treatment strategies are now based not only on accurate diagnosis but also on thorough evaluation of clinical and molecular risk factors. Even more importantly, molecular targeted approaches have been shown to be effective in the treatment of distinct lymphoma subtypes. Against this background, clinical management of especially the rare lymphomas remains a challenge for the general oncologist. This book provides a

comprehensive overview of current treatment strategies in these rare

describe the histomorphology in a clinically relevant manner, consider

lymphoma subtypes. Experts in the field from around the world

the role of risk factors in detail, and discuss the spectrum of therapeutic approaches. Special emphasis is placed on the translation of molecular science into clinical care, and a disease-specific algorithm is proposed for each entity. This book will prove an excellent resource for both experienced and inexperienced practitioners.